UA100727C2 - Соединение, содержащее модифицированный олигонуклеотид, комплементарный mir-21 или его предшественнику, для лечения, профилактики или диагностики фиброза или фибропролиферативного заболевания - Google Patents

Соединение, содержащее модифицированный олигонуклеотид, комплементарный mir-21 или его предшественнику, для лечения, профилактики или диагностики фиброза или фибропролиферативного заболевания

Info

Publication number
UA100727C2
UA100727C2 UAA201011410A UAA201011410A UA100727C2 UA 100727 C2 UA100727 C2 UA 100727C2 UA A201011410 A UAA201011410 A UA A201011410A UA A201011410 A UAA201011410 A UA A201011410A UA 100727 C2 UA100727 C2 UA 100727C2
Authority
UA
Ukraine
Prior art keywords
modified oligonucleotide
mir
fibrosis
diagnostics
precursor
Prior art date
Application number
UAA201011410A
Other languages
English (en)
Ukrainian (uk)
Inventor
Томас Тум
Йоханн Бауерзахс
Штефан Энгельхардт
Карина Гросс
Original Assignee
Юлиус Максимилианс-Универзитет Вюрцбург
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юлиус Максимилианс-Универзитет Вюрцбург filed Critical Юлиус Максимилианс-Универзитет Вюрцбург
Publication of UA100727C2 publication Critical patent/UA100727C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)

Abstract

Изобретение относится к соединению, содержащему модифицированный олигонуклеотид, состоящий из 12-30 соединенных друг с другом нуклеозидов, при этом указанный модифицированный олигонуклеотид содержит последовательность нуклеиновых основ, комплементарному miR-21 или его предшественнику, для применения в лечении, профилактике или диагностике фиброза или фибропролиферативного заболевания у индивида.
UAA201011410A 2008-02-27 2009-02-26 Соединение, содержащее модифицированный олигонуклеотид, комплементарный mir-21 или его предшественнику, для лечения, профилактики или диагностики фиброза или фибропролиферативного заболевания UA100727C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20080003570 EP2096171A1 (en) 2008-02-27 2008-02-27 MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
PCT/EP2009/001590 WO2009106367A1 (en) 2008-02-27 2009-02-26 Microrna (mirna) and downstream targets for diagnostic and therapeutic purposes

Publications (1)

Publication Number Publication Date
UA100727C2 true UA100727C2 (ru) 2013-01-25

Family

ID=39639202

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201011410A UA100727C2 (ru) 2008-02-27 2009-02-26 Соединение, содержащее модифицированный олигонуклеотид, комплементарный mir-21 или его предшественнику, для лечения, профилактики или диагностики фиброза или фибропролиферативного заболевания

Country Status (24)

Country Link
US (10) US8236777B2 (ru)
EP (3) EP2096171A1 (ru)
JP (2) JP6033527B2 (ru)
KR (1) KR101697482B1 (ru)
CN (1) CN102027113B (ru)
AU (1) AU2009218704C1 (ru)
BR (1) BRPI0907565B1 (ru)
CA (2) CA2716643C (ru)
CY (1) CY1114426T1 (ru)
DK (1) DK2260101T3 (ru)
EA (1) EA020335B1 (ru)
ES (1) ES2436885T3 (ru)
HK (1) HK1150857A1 (ru)
HR (1) HRP20130766T1 (ru)
IL (1) IL207704A (ru)
ME (1) ME01600B (ru)
MX (2) MX336299B (ru)
MY (1) MY159454A (ru)
NZ (1) NZ588185A (ru)
PL (1) PL2260101T3 (ru)
PT (1) PT2260101E (ru)
SI (1) SI2260101T1 (ru)
UA (1) UA100727C2 (ru)
WO (2) WO2009106477A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322616A1 (en) 2004-11-12 2011-05-18 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
WO2011017697A1 (en) * 2009-08-07 2011-02-10 New York University Compositions and methods for treating inflammatory disorders
CN102038959B (zh) * 2009-10-26 2012-12-19 中国科学院上海生命科学研究院 let-7/miR-98家族在制备治疗FAS基因相关疾病的药物中的应用
WO2011126842A2 (en) * 2010-03-30 2011-10-13 Regulus Therapeutics Inc. Targeting micrornas for the treatment of cardiac disorders
WO2011154553A2 (en) 2010-06-11 2011-12-15 Cellartis Ab Novel micrornas for the detection and isolaton of human embryonic stem cell-derived cardiac cell types
US8815826B2 (en) 2010-07-23 2014-08-26 Regulus Therapeutics, Inc. Targeting microRNAs for the treatment of fibrosis
KR20140004646A (ko) * 2010-12-15 2014-01-13 미라젠 세러퓨틱스 잠금 뉴클레오티드를 포함하는 마이크로rna 억제제
SI3211082T1 (sl) * 2011-04-25 2021-08-31 Sanofi Spojine mikroRNA in postopki za spreminjanje delovanja MIR-21
ES2651515T3 (es) * 2011-09-06 2018-01-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. La familia miARN-212/132 como diana terapéutica
KR20140091688A (ko) 2011-10-06 2014-07-22 미라젠 세러퓨틱스 인코포레이티드 마이크로rna 조절에 의한 전신 에너지 항상성의 제어
EP2592145A1 (en) * 2011-11-11 2013-05-15 Medizinische Hochschule Hannover Medicament for the treatment of cardiac disease
MX2014006130A (es) * 2011-11-22 2015-04-13 Intermune Inc Metodos de diagnostico y tratamiento de la fibrosis pulmonar idiopatica.
JP2015501843A (ja) * 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
EP2836219A1 (en) * 2012-04-10 2015-02-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for the treatment of nonalcoholic steatohepatitis
BR112014026639A8 (pt) * 2012-04-25 2018-01-16 Regulus Therapeutics Inc compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto.
ES2801875T3 (es) 2012-06-21 2021-01-14 Miragen Therapeutics Inc Inhibidores basados en oligonucleótidos que comprenden un motivo de ácido nucleico bloqueado
CA2782942C (en) * 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
UA116639C2 (uk) 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
US11007221B2 (en) 2013-07-12 2021-05-18 Canadian Blood Services Acellular pro-inflammatory compositions, process for making same and methods of using same
EP3060664B1 (en) 2013-10-25 2021-07-07 Sanofi Microrna compounds and methods for modulating mir-21 activity
WO2015086828A1 (en) * 2013-12-12 2015-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
CA2954440A1 (en) 2014-07-10 2016-01-14 Canadian Blood Services Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system
CA2960387A1 (en) * 2014-09-08 2016-03-17 MiRagen Therapeutics, Inc. Mir-29 mimics and uses thereof
EA201791644A1 (ru) 2015-01-20 2018-01-31 Мираджен Терапьютикс, Инк. Ингибиторы mir-92 и их применение
CN106924757B (zh) * 2015-12-31 2020-07-24 中国科学院遗传与发育生物学研究所 miR-449c-5p及其拟似物在制备治疗和预防心脏瓣膜疾病产品中的应用
CN107034216A (zh) * 2016-02-04 2017-08-11 中国科学技术大学 miRancer分子的设计与应用
KR101835018B1 (ko) 2016-03-03 2018-03-06 고려대학교 산학협력단 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
WO2019050071A1 (ko) 2017-09-08 2019-03-14 고려대학교 산학협력단 엑소좀 또는 엑소좀 유래 리보핵산을 포함하는 간섬유증 예방 또는 치료용 조성물
CN107858419A (zh) * 2017-11-10 2018-03-30 青岛大学 miRNA的应用、应用其的产品及检测方法
MX2020012652A (es) 2018-05-25 2021-05-27 Bioneer Corp Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo.
CN109498642A (zh) * 2018-12-21 2019-03-22 复旦大学附属中山医院 一种柯萨奇b3病毒感染导致的心脏微血管病变的靶向治疗药物
EP4133075A1 (en) 2020-04-09 2023-02-15 Technische Universität München Targeted delivery of an inhibitor of mir-21 to macrophages for the treatment of pulmonary fibrosis
US20230302139A1 (en) * 2020-07-31 2023-09-28 University Of Florida Research Foundation, Incorporated Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna
WO2022184888A2 (en) * 2021-03-05 2022-09-09 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for use in the treatment of corneal dystrophies
KR102549208B1 (ko) * 2021-04-08 2023-06-30 연세대학교 산학협력단 심혈관 질환과 관련된 LncRNA 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060247193A1 (en) * 2003-02-10 2006-11-02 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference
WO2004083430A2 (en) * 2003-03-21 2004-09-30 Santaris Pharma A/S SHORT INTERFERING RNA (siRNA) ANALOGUES
KR20130105741A (ko) * 2003-11-17 2013-09-25 노파르티스 아게 디펩티딜 펩티다제 ⅳ 억제제의 용도
AU2005243410B2 (en) 2004-05-14 2010-04-22 Rosetta Genomics Ltd. Micronas and uses thereof
EP1827458A4 (en) * 2004-11-09 2010-02-17 Baylor College Medicine SELECTIVE INHIBITION OF ROCK 1 IN CARDIAC THERAPY
US20070213292A1 (en) * 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007112753A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2094869B1 (de) 2006-10-09 2012-07-25 Julius-Maximilians-Universität Würzburg Microrna (mirna) zur diagnose und therapie von herzerkrankungen
CA2671294A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2009058818A2 (en) 2007-10-29 2009-05-07 The Board Of Regents Of The University Of Texas System Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling
EP2096171A1 (en) 2008-02-27 2009-09-02 Julius-Maximilians-Universität Würzburg MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes

Also Published As

Publication number Publication date
MX2010009346A (es) 2010-12-20
WO2009106477A1 (en) 2009-09-03
IL207704A0 (en) 2010-12-30
US8236777B2 (en) 2012-08-07
ME01600B (me) 2014-09-20
EA201070992A1 (ru) 2011-04-29
JP2011516410A (ja) 2011-05-26
EP2096171A1 (en) 2009-09-02
EA020335B1 (ru) 2014-10-30
CA2716643C (en) 2021-08-03
IL207704A (en) 2016-11-30
CY1114426T1 (el) 2016-08-31
US9220722B2 (en) 2015-12-29
NZ588185A (en) 2012-11-30
MX336299B (es) 2016-01-14
KR20100126430A (ko) 2010-12-01
JP2015107971A (ja) 2015-06-11
US20200069720A1 (en) 2020-03-05
BRPI0907565A2 (pt) 2019-05-28
EP2260101B1 (en) 2013-05-29
US20160177302A1 (en) 2016-06-23
HK1150857A1 (en) 2012-01-13
AU2009218704C1 (en) 2015-01-29
US20170304347A1 (en) 2017-10-26
CA2716643A1 (en) 2009-09-03
CN102027113B (zh) 2017-08-18
US9663788B2 (en) 2017-05-30
PT2260101E (pt) 2013-09-05
WO2009106367A1 (en) 2009-09-03
US8592389B2 (en) 2013-11-26
US20180360866A1 (en) 2018-12-20
ES2436885T3 (es) 2014-01-07
EP2628800A1 (en) 2013-08-21
US20130018084A1 (en) 2013-01-17
AU2009218704B2 (en) 2014-09-18
US20210113603A1 (en) 2021-04-22
CA3123067A1 (en) 2009-09-03
US10028974B2 (en) 2018-07-24
BRPI0907565B1 (pt) 2021-11-30
PL2260101T3 (pl) 2013-10-31
US20110071211A1 (en) 2011-03-24
AU2009218704A1 (en) 2009-09-03
EP2260101A1 (en) 2010-12-15
MY159454A (en) 2017-01-13
HRP20130766T1 (hr) 2013-10-25
SI2260101T1 (sl) 2013-10-30
JP6033527B2 (ja) 2016-11-30
DK2260101T3 (da) 2013-08-19
KR101697482B1 (ko) 2017-01-18
US20140121264A1 (en) 2014-05-01
US10434117B2 (en) 2019-10-08
US20230028937A1 (en) 2023-01-26
CN102027113A (zh) 2011-04-20
US20240189339A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
UA100727C2 (ru) Соединение, содержащее модифицированный олигонуклеотид, комплементарный mir-21 или его предшественнику, для лечения, профилактики или диагностики фиброза или фибропролиферативного заболевания
EP4219516A3 (en) Chiral control
WO2007128477A3 (en) SHORT INTERFERING RIBONUCLEIC ACID (siRNA) FOR ORAL ADMINISTRATION
WO2009140626A3 (en) Long term disease modification using immunostimulatory oligonucleotides
SI2143792T1 (sl) Enoverižna ciklična RNA in postopek za njeno pripravo
WO2010056982A3 (en) Compositions and methods for identifying autism spectrum disorders
EP2431465A4 (en) METHOD FOR SYNTHESIS OF DOUBLE-STRENGTHED DNA ACCORDING TO AN RNA AND METHOD FOR DNA AMPLIFICATION
EP2170919A4 (en) IMPROVED PROCESS FOR THE PRODUCTION OF NUCLEOTIDE SUGARS
HK1210137A1 (en) Process for the preparation of 2,3,3,3-tetrafluoropropene 2333-
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
WO2011133876A3 (en) Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011097644A3 (en) Selective reduction of allelic variants
ZA201007526B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
HK1153728A1 (zh) 製備 -四氟丙烯的方法
IL215682A0 (en) Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
WO2008091703A3 (en) Chemically modified oligonucleotides for use in modulating micro rna and uses thereof
WO2009065738A3 (de) Polyoxyalkylenamine zur verbesserten duftausbeute
SI2504334T1 (sl) Postopek čiščenja (4,6-diamino-2-(1-(2-fluorobenzil)-1H-pirazolo-(3,4-b)piridin-3-il)piri midin-5-il)metilkarbamata
WO2007035771A3 (en) Modulation of glucagon receptor expression
WO2009047610A8 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
WO2007131495A3 (de) Multimer zur immunstimulation
IL208732A (en) Methods for producing morphogenetic protein of bones number 2 bmp
WO2010071852A3 (en) Oligonucleotide micelles
MX2018002998A (es) Derivado de acido nucleico que tiene actividad inmunoestimuladora.
WO2008142513A3 (en) Phosphate-modified oligonucleotide analogs with immunostimulatory activity